| abstract |
The present invention includes, for example, GPR119-receptor-related disorders; Conditions improved by an increase in incretin secretion; Conditions improved by an increase in blood incretin levels; Conditions characterized by low bone mass; Nervous system disorders; Metabolic-related disorders; Type 2 diabetes; obesity; And in the treatment of a disorder selected from the complications associated therewith, as a single pharmaceutical agent or one or more additional pharmaceutical agents such as DPP-IV inhibitors, biguanides, alpha-glucosidase inhibitors, insulin analogues, sulfonylureas, SGLT2 inhibitors. GPR119 receptor agonists useful in combination with, meglitinide, thiazolidinediones or antidiabetic peptide analogs: 3-fluoro-4- (5-fluoro-6- (4- (3- (2-fluoro) Ropropan-2-yl) -1,2,4-oxadiazol-5-yl) piperidin-1-yl) pyrimidin-4-ylamino) -N, N-dimethylbenzamide; 3-fluoro-4- (5-fluoro-6- (4- (3- (2-fluoropropan-2-yl) -1,2,4-oxadiazol-5-yl) piperidine -1-yl) pyrimidin-4-ylamino) -N-methylbenzamide; And 3-fluoro-4- (5-fluoro-6- (4- (3- (2-fluoropropan-2-yl) -1,2,4-oxadiazol-5-yl) piperi Din-1-yl) pyrimidin-4-ylamino) benzamide, and pharmaceutically acceptable salts, solvates and hydrates thereof. |